Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Amalgamated Bank

Amalgamated Bank reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 3.5% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 50,283 shares of the life sciences company’s stock after selling 1,835 shares during the period. Amalgamated Bank owned approximately 0.06% of Integra LifeSciences worth $3,231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IART. American Trust purchased a new position in Integra LifeSciences in the 1st quarter worth approximately $313,000. Point72 Hong Kong Ltd increased its holdings in Integra LifeSciences by 59.6% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,858 shares of the life sciences company’s stock valued at $248,000 after purchasing an additional 1,441 shares during the last quarter. Quantbot Technologies LP increased its holdings in Integra LifeSciences by 1,100.6% in the 1st quarter. Quantbot Technologies LP now owns 5,979 shares of the life sciences company’s stock valued at $384,000 after purchasing an additional 5,481 shares during the last quarter. Eaton Vance Management increased its holdings in Integra LifeSciences by 2.6% in the 1st quarter. Eaton Vance Management now owns 4,216,174 shares of the life sciences company’s stock valued at $270,931,000 after purchasing an additional 108,831 shares during the last quarter. Finally, First Republic Investment Management Inc. increased its holdings in Integra LifeSciences by 8.8% in the 1st quarter. First Republic Investment Management Inc. now owns 5,899 shares of the life sciences company’s stock valued at $379,000 after purchasing an additional 479 shares during the last quarter. 87.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Integra LifeSciences

In other news, EVP Lisa Evoli sold 1,165 shares of the company’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $55.81, for a total value of $65,018.65. Following the completion of the sale, the executive vice president now directly owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Raymond G. Murphy sold 8,000 shares of the company’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $55.78, for a total value of $446,240.00. Following the completion of the sale, the director now directly owns 40,825 shares of the company’s stock, valued at $2,277,218.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Lisa Evoli sold 1,165 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $55.81, for a total transaction of $65,018.65. Following the transaction, the executive vice president now owns 17,997 shares in the company, valued at $1,004,412.57. The disclosure for this sale can be found here. Insiders sold a total of 9,602 shares of company stock valued at $536,067 over the last ninety days. Insiders own 4.20% of the company’s stock.

Integra LifeSciences Price Performance

Shares of IART opened at $43.39 on Friday. Integra LifeSciences Holdings Co. has a 1-year low of $43.07 and a 1-year high of $74.98. The stock has a market cap of $3.62 billion, a PE ratio of 22.03, a price-to-earnings-growth ratio of 1.47 and a beta of 1.12. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.85 and a quick ratio of 2.76. The firm has a fifty day moving average price of $51.77 and a 200 day moving average price of $57.34.

Integra LifeSciences (NASDAQ:IARTGet Rating) last announced its quarterly earnings results on Wednesday, July 27th. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.02. Integra LifeSciences had a net margin of 10.61% and a return on equity of 16.72%. The firm had revenue of $397.82 million during the quarter, compared to analysts’ expectations of $394.54 million. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 3.16 EPS for the current year.

Wall Street Analysts Forecast Growth

IART has been the subject of several research reports. TheStreet downgraded shares of Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Friday, July 8th. Morgan Stanley dropped their price target on shares of Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating for the company in a research note on Thursday, August 25th. Truist Financial dropped their price target on shares of Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating for the company in a research note on Wednesday, July 20th. Finally, Piper Sandler dropped their price target on shares of Integra LifeSciences from $55.00 to $50.00 in a research note on Wednesday, August 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $65.43.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Featured Stories

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.